NASDAQ:NKTR - Nektar Therapeutics Stock Price, Forecast & News

$23.13

+0.28 (+1.23 %)

(As of 02/16/2020 04:00 PM ET)

Add

Today's Range

$22.47

Now: $23.13▼

$23.60

50-Day Range

$19.77

MA: $22.25▼

$27.96

52-Week Range

$15.64

Now: $23.13▼

$44.06

Volume2.16 million shs

Average VolumeN/A

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry N/A

Sub-IndustryPharmaceuticals

SectorN/A

Current SymbolNASDAQ:NKTR

Previous Symbol

CUSIP64026810

CIK906709

WebN/A

PhoneN/A

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Employees618

Outstanding SharesN/A

Market CapN/A

Next Earnings Date2/27/2020 (Estimated)

OptionableOptionable

Receive NKTR News and Ratings via Email

Sign-up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter.

Nektar Therapeutics (NASDAQ:NKTR) Frequently Asked Questions

What is Nektar Therapeutics' stock symbol?

Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."

How were Nektar Therapeutics' earnings last quarter?

Nektar Therapeutics (NASDAQ:NKTR) announced its quarterly earnings data on Wednesday, November, 6th. The biopharmaceutical company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.17. The biopharmaceutical company had revenue of $29.22 million for the quarter, compared to analyst estimates of $26.42 million. The firm's revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.56) earnings per share. View Nektar Therapeutics' Earnings History.

When is Nektar Therapeutics' next earnings date?

Nektar Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Nektar Therapeutics.

What price target have analysts set for NKTR?

14 analysts have issued twelve-month target prices for Nektar Therapeutics' shares. Their forecasts range from $16.00 to $41.00. On average, they expect Nektar Therapeutics' stock price to reach $30.54 in the next twelve months. This suggests a possible upside of 32.0% from the stock's current price. View Analyst Price Targets for Nektar Therapeutics.

What is the consensus analysts' recommendation for Nektar Therapeutics?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last year. There are currently 1 sell rating, 7 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Nektar Therapeutics.

What are Wall Street analysts saying about Nektar Therapeutics stock?

Here are some recent quotes from research analysts about Nektar Therapeutics stock:

1. According to Zacks Investment Research, "Nektar has a promising pipeline with several regulatory updates/data-readouts lined up for the next several quarters. Moreover, regular partnerships have enhanced the company’s financial position. The blockbuster collaboration deal with Bristol-Myers for NKTR-214 significantly boosted Nektar’s cash resources. It also has encouraging co-development deals with other pharma companies. The deals boost revenues and reduce expenses by sharing research costs. On the flip side, Nektar relies heavily on partners for revenues. Partnership-related setbacks may thus weigh heavily on the company’s results in the future. Shares of the company have underperformed the industry in the past year." (1/13/2020)
2. HC Wainwright analysts commented, "Our new 12-month, $24, vs. our prior $47 target on shares of Nektar is based on a 12-year DCF-driven, sum-of-the-parts analysis. Our DCF is driven by beta of 1.62, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.0%, and tax rate of 15% beginning in FY 2027." (8/13/2019)
3. William Blair analysts commented, "We traveled with LeMaitre management last week as the company met with Barrington clients in Richmond, VA. This marked the second time in a month that we have spent time on the road with members of this management team and the messaging remains consistent and long-term bullish despite some short-term challenges." (6/14/2019)
4. Mizuho analysts commented, "We expect these events to be important drivers for NKTR shares as we continue to believe that a majority of the company’s value lies in NKTR-214." (3/1/2019)

Has Nektar Therapeutics been receiving favorable news coverage?

Media coverage about NKTR stock has been trending extremely negative this week, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Nektar Therapeutics earned a news sentiment score of -5.0 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Nektar Therapeutics.

Who are some of Nektar Therapeutics' key competitors?

Some companies that are related to Nektar Therapeutics include AbbVie (ABBV), The Medicines (MDCO), Assembly Biosciences (ASMB), Ampio Pharmaceuticals (AMPE), Melinta Therapeutics (MLNT), Acura Pharmaceuticals (ACUR), Akorn (AKRX), Allergan (AGN), BioDelivery Sciences International (BDSI), Bristol-Myers Squibb (BMY), Corcept Therapeutics (CORT), Cumberland Pharmaceuticals (CPIX), Eli Lilly And Co (LLY), Endo International (ENDP) and Horizon Therapeutics (HZNP).

What other stocks do shareholders of Nektar Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Hawkins (HWKN), Incyte (INCY), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Netflix (NFLX), Intel (INTC) and AT&T (T).

Who are Nektar Therapeutics' key executives?

Nektar Therapeutics' management team includes the folowing people:

Mr. Howard W. Robin, CEO, Pres & Director (Age 66)
Mr. Gil M. Labrucherie, Sr. VP & CFO (Age 47)
Mr. John Nicholson, Sr. VP & COO (Age 67)
Dr. Maninder Hora, Sr. VP of Pharmaceutical Devel. & Chief Technical Operations Officer (Age 65)
Dr. Stephen K. Doberstein, Chief R&D Officer (Age 60)

Who are Nektar Therapeutics' major shareholders?

Nektar Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (8.49%), State Street Corp (2.59%), Maverick Capital Ltd. (1.84%), First Trust Advisors LP (1.69%), Goldman Sachs Group Inc. (1.11%) and Bank of New York Mellon Corp (1.04%). Company insiders that own Nektar Therapeutics stock include Christopher A Kuebler, Dennis L Winger, Gil M Labrucherie, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, John Nicholson, Jonathan Zalevsky, Katharina Otto-Bernstein, Lutz Lingnau, Maninder Hora, R Scott Greer, Robert Chess and Stephen K Doberstein. View Institutional Ownership Trends for Nektar Therapeutics.

Which major investors are selling Nektar Therapeutics stock?

NKTR stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Charles Schwab Investment Management Inc., UBS Asset Management Americas Inc., Swiss National Bank, Retirement Systems of Alabama, Bank of America Corp DE, Pictet Asset Management Ltd. and Credit Suisse AG. Company insiders that have sold Nektar Therapeutics company stock in the last year include Gil M Labrucherie, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, John Nicholson, Jonathan Zalevsky, Katharina Otto-Bernstein, Lutz Lingnau, Maninder Hora, Robert Chess and Stephen K Doberstein. View Insider Buying and Selling for Nektar Therapeutics.

Which major investors are buying Nektar Therapeutics stock?

NKTR stock was purchased by a variety of institutional investors in the last quarter, including Maverick Capital Ltd., FMR LLC, Goldman Sachs Group Inc., Principal Financial Group Inc., KBC Group NV, Bank of New York Mellon Corp, First Trust Advisors LP and American International Group Inc.. View Insider Buying and Selling for Nektar Therapeutics.

How do I buy shares of Nektar Therapeutics?

Shares of NKTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Nektar Therapeutics' stock price today?

One share of NKTR stock can currently be purchased for approximately $23.13.

MarketBeat Community Rating for Nektar Therapeutics (NASDAQ NKTR)

Community Ranking:		3.1 out of 5 ( )
Outperform Votes:		595 (Vote Outperform)
Underperform Votes:		377 (Vote Underperform)
Total Votes:		972

MarketBeat's community ratings are surveys of what our community members think about Nektar Therapeutics and other stocks. Vote "Outperform" if you believe NKTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NKTR will underperform the S&P 500 over the long term. You may vote once every thirty days.

This page was last updated on 2/16/2020 by MarketBeat.com Staff

Your Ultimate Investing Toolkit

Just $1.00 for your first month.